Core Viewpoint - Rosen Law Firm is reminding investors who purchased Kyverna Therapeutics, Inc. common stock during its IPO on February 8, 2024, about the upcoming lead plaintiff deadline of February 7, 2025 [1] Group 1: Class Action Information - Investors who bought Kyverna common stock may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6] - To serve as lead plaintiff, individuals must file a motion with the Court by February 7, 2025 [3] Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4] - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time, and has recovered hundreds of millions for investors [4] Group 3: Case Details - The lawsuit claims that Kyverna's IPO registration statement and prospectus contained misstatements and omissions regarding the clinical trial results of its lead product candidate, KYV-101 [5] - Kyverna allegedly highlighted patient "improvement" while failing to disclose adverse data known at the time of the IPO, leading to investor damages when the true information became public [5]
ROSEN, LEADING INVESTOR COUNSEL, Encourages Kyverna Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – KYTX